SHORT COMMUNICATIONSHer2 overexpression is a rare event in anorectal melanomaHelmke, Burkhard Mariaa b; Zahel, Tinaa; Breinig, Marcoa; Schirmacher, Petera; Aulmann, Sebastiana; Kern, Michael AndréaAuthor Information aDepartment of General Pathology, Heidelberg University Hospital, Heidelberg bInstitute of Pathology, Elbe Kliniken Stade, Stade, Germany Correspondence to Professor Michael André Kern, MD, Department of General Pathology, Heidelberg University Hospital, INF 220/221, 69120 Heidelberg, Germany Tel: +49 6221 56 2690; fax: +49 6221 56 5251; e-mail: [email protected] Received 18 December 2009 Accepted 30 March 2010 Melanoma Research: October 2010 - Volume 20 - Issue 5 - p 431-434 doi: 10.1097/CMR.0b013e32833ab159 Buy Metrics Abstract Anorectal melanomas (AMs) are very rare and highly malignant tumors that are often diagnosed in advanced stages. After the differentiation between cutaneous melanoma (CM) and AM on the molecular level based on the presence of BRAF mutations, further modes of differentiation opened up, such as the recently discovered immunohistologically relevant protein deleted in malignant brain tumors 1 (DMBT1). Over the past several years, increasingly specific therapies have been developed on the basis of new therapy principles. Tyrosin kinase receptors such as Her2 and EGFR have been awarded a large role in this context. The goal of this study was to examine AMs for a possible expression or overexpression of these markers. Expression analyses of Her2 and EGFR were performed immunohistologically on 25 primary AMs. An overexpression of Her2 (score: 3+) was found in one AM from a 68-year-old female patient among these samples. In contrast, EGFR expression was not found in any of the AMs. The results presented here show that isolated cases of AM may benefit from an additive Her2-directed therapy, as the overexpression of Her2 was found in one of our AM patients. © 2010 Lippincott Williams & Wilkins, Inc.